What Is Life Expectancy After Immunotherapy?

There is no single life expectancy number after immunotherapy because outcomes vary enormously by cancer type, stage, treatment regimen, and individual biology. But the broad story is striking: immunotherapy has created a population of long-term cancer survivors in diseases where five-year survival was once almost unheard of. In advanced melanoma, the cancer with the longest follow-up data, a landmark ten-year trial reported median overall survival of nearly six years with combination immunotherapy, and more than a third of patients were still alive at the end of the study. Other cancers show less dramatic but still meaningful gains, and the pattern of response is unlike anything seen with older treatments.

The Tail of the Survival Curve

Immunotherapy produces a survival pattern that oncologists call the “tail of the curve.” With chemotherapy, survival curves tend to drop steadily over time as patients relapse one by one. With checkpoint inhibitors, the curve also drops early, but then it flattens. A meaningful fraction of patients reach a plateau where they remain alive for years, sometimes without any further treatment. This plateau is the “tail,” and it reflects the durability of immune responses: once the immune system learns to recognize and attack cancer cells, that surveillance can persist long after the drug is stopped.

A case report in metastatic lung adenocarcinoma illustrated this well. A patient discontinued all treatment after 18 months but maintained disease control for an additional 36 months, consistent with a pronounced tail effect from combined immunotherapy and anti-angiogenic therapy.¹ This durability is what separates immunotherapy from most prior cancer treatments and why asking about “life expectancy” requires understanding the shape of survival, not just the median.

In non-small cell lung cancer, a large trial of nivolumab plus ipilimumab versus chemotherapy showed how this plays out in practice. The median overall survival was about 17 months with immunotherapy versus 15 months with chemotherapy, a modest-sounding difference. But the survival curves told a different story: chemotherapy patients did slightly better initially, while the immunotherapy group pulled ahead over time as their curve flattened and the chemotherapy curve kept falling. Two-year survival was 40% with the combination versus about 33% with chemotherapy.²

Melanoma Has the Longest Track Record

Advanced melanoma was the first cancer where modern checkpoint inhibitors proved their worth, and it now has the most mature survival data. The ten-year results from the CheckMate 067 trial, published in the New England Journal of Medicine, provide the clearest picture of what durable immunotherapy survival looks like. Patients who received nivolumab plus ipilimumab had a median overall survival of 71.9 months, meaning half lived beyond nearly six years. Nivolumab alone produced a median of about 37 months, and ipilimumab alone about 20 months. Among the combination group, melanoma-specific survival had not been reached at the end of the study, with 37% of patients still alive.³

Real-world data from a large cohort of advanced melanoma patients broadly supported these figures, though with slightly lower numbers as you would expect outside of a controlled trial. Five-year overall survival across all patients was about 36%, with those receiving the combination of ipilimumab and nivolumab reaching roughly 41% at five years, compared to about 39% for single-agent anti-PD-1 therapy and 25% for ipilimumab alone.⁴ For a disease that had a median survival measured in months just fifteen years ago, these numbers represent a fundamental shift.

Lung Cancer Survival With Immunotherapy

Non-small cell lung cancer is the most common setting for immunotherapy worldwide, and outcomes here are more modest than in melanoma but still represent a genuine improvement over chemotherapy alone. In the KEYNOTE-001 trial, patients with advanced lung cancer treated with pembrolizumab had a five-year overall survival of about 23% if they were treatment-naive and roughly 16% if they had received prior therapies. Patients whose tumors had high levels of the PD-L1 biomarker did better, with five-year survival reaching about 30% in the treatment-naive group.⁵

The KEYNOTE-024 trial focused specifically on patients with high PD-L1 expression and found a median overall survival of about 26 months with pembrolizumab versus 13 months with chemotherapy. The five-year survival rate was roughly 32% in the pembrolizumab group. Among patients who completed a full two-year course of treatment, over 80% were still alive at approximately five years.⁶ That last number is worth dwelling on: if you respond well enough to finish two years of treatment, your odds of being alive three years later are very good.

Immunotherapy is also moving into earlier-stage lung cancer. In the KEYNOTE-671 trial, patients with resectable disease who received pembrolizumab before and after surgery had a three-year overall survival of 71% compared to 64% with surgery and chemotherapy alone.⁷ These are earlier-stage patients with better baseline prognoses, so the absolute numbers are higher, but the relative benefit of adding immunotherapy was clear.

CAR-T Cell Therapy and Blood Cancers

CAR-T cell therapy, a different branch of immunotherapy that involves engineering a patient’s own immune cells, has produced some of the most dramatic long-term data in blood cancers. Ten-year follow-up of patients with B-cell lymphomas treated with CAR-T cells showed that no relapses occurred beyond about five and a half years. For large B-cell lymphoma, the ten-year lymphoma-free survival was 32%, and for follicular lymphoma it was 47%. Overall survival at ten years was 17% for large B-cell lymphoma and 50% for follicular lymphoma.⁸

The absence of late relapses is a big deal. It suggests that for the patients who do respond durably, CAR-T therapy is genuinely curative rather than simply delaying the inevitable. A broader review confirmed that CAR-T cells targeting CD19 can produce prolonged remissions with minimal long-term toxicities and are likely curative for a subset of patients with B-cell cancers.⁹

Why Depth of Response Matters So Much

One of the strongest predictors of long-term survival after immunotherapy is how completely the cancer responds. Patients who achieve a complete response, where no detectable cancer remains on scans, have dramatically better outcomes than those with partial responses. In metastatic melanoma, patients who achieved a complete response to pembrolizumab had a two-year disease-free survival of about 91%, and this held even for patients who stopped treatment after their complete response.¹⁰ A separate study of melanoma patients found that five-year overall survival after complete response was 83%.¹¹

This pattern extends to other cancers. In liver cancer, complete responders to immunotherapy had two-year overall survival rates of about 81% to 93%, depending on the cohort studied.¹² The implication for patients is that the initial response to treatment is highly informative about long-term prognosis. A deep, complete response is the best-case scenario and often predicts years of disease control.

Real-World Survival Falls Short of Trial Results

Clinical trial numbers consistently overestimate what happens when these drugs are used in typical practice. Trial participants are younger, fitter, and more carefully selected than the general cancer population. A Dutch study comparing real-world outcomes for lung cancer patients on immunotherapy found that overall survival with first-line pembrolizumab was about 16 months in practice versus the much longer survival seen in the registration trial. One-year survival was 57% in the real world versus 70% in the trial.¹³

A larger international study confirmed this pattern across multiple treatment regimens, finding that real-world median overall survival was roughly 36% to 61% shorter than the corresponding trial results. Patients with poorer physical function showed even larger gaps between real-world and trial outcomes.¹⁴ This is an important reality check: the five-year survival percentages from landmark trials are the best-case benchmark, not a guaranteed average.

Combination Therapy, Treatment Duration, and Practical Decisions

Whether to use immunotherapy alone or combined with chemotherapy depends partly on tumor biology. For lung cancer patients with moderate levels of PD-L1 expression, adding chemotherapy to pembrolizumab improved median survival to about 21 months compared to roughly 14 months with pembrolizumab alone.¹⁵ For patients with very high PD-L1 levels, the advantage of adding chemotherapy narrows, and single-agent immunotherapy is often sufficient.

A common question patients have is how long to stay on treatment. Most immunotherapy trials use a fixed duration of about two years, but some oncologists continue treatment indefinitely if it is working. A study of lung cancer patients found no significant difference in overall survival between those who stopped at a fixed duration and those who continued indefinitely. Two-year survival from the stopping point was about 79% in the fixed-duration group and 81% in the indefinite group.¹⁶ For patients doing well, stopping treatment after two years appears to be a reasonable option.

When Immunotherapy Stops Working

Not all patients maintain their response. Acquired resistance is a growing area of concern, and researchers have identified several mechanisms by which tumors learn to evade the immune system. Tumors can lose the ability to present their identifying markers to immune cells, can activate alternative immune-suppressing pathways, or can alter the signaling that recruits immune cells.¹⁷ One study found that tumors under heavy immune attack can selectively lose specific molecules that immune cells use to identify them, essentially going invisible to the very cells trained to destroy them.¹⁸

When disease progresses after immunotherapy, restarting treatment, either with the same drug or a different one, can still work for some patients. A systematic review of lung cancer patients found that those who received immunotherapy rechallenge after progression had better survival outcomes than those who moved on to other treatments, with a roughly 35% reduction in the risk of death.¹⁹ In kidney cancer, restarting checkpoint inhibitors after they had been stopped for side effects produced new responses in about 23% of patients who had not responded before, with two-year overall survival reaching 76% in the retreatment group.²⁰

Who Benefits Most and Who Faces Greater Risk

Several factors help predict who will do well on immunotherapy. Tumors with high PD-L1 expression or with a feature called microsatellite instability tend to respond better, though both markers have real limitations, including variability in testing methods and differences within a single tumor.²¹ The gut microbiome has also emerged as an unexpected factor. In melanoma patients, specific bacterial populations present before treatment were associated with longer survival after immunotherapy.²² Similar patterns have been observed in brain tumors, where bacteria in the Firmicutes group were enriched in patients who lived longer.²³ This research is still early, and nobody should be making treatment decisions based on a stool test, but it suggests future tools for predicting outcomes.

Age is less of a barrier than many patients fear. A review of immunotherapy studies in older adults found that survival rates were generally comparable between younger and older patients, and side-effect rates varied only slightly by age.²⁴ Fitness matters more than the calendar.

People with pre-existing autoimmune diseases face a different calculation. A study of over 500 patients found that those with autoimmune conditions had roughly 1.8 times the risk of cardiovascular events after immunotherapy, along with higher rates of colitis and skin flares, compared to matched patients without autoimmune disease.²⁵ Organ transplant recipients face even more acute risks: kidney transplant rejection has occurred within days of starting immunotherapy.²⁶ These patients are not automatically excluded from treatment, but the risk-benefit calculation is different and requires careful discussion with their oncologist.

Living After Immunotherapy

For patients who survive long-term, quality of life is generally good, but not without asterisks. A study of melanoma survivors who had been treated with checkpoint inhibitors found that overall functioning was high and quality of life was rated as excellent. However, about 28% reported fatigue, 17% had aching joints, and 40% described some degree of anxiety or depression.²⁷ Another study noted chronic side effects including thyroid problems in about 11% of survivors, along with smaller percentages experiencing arthritis, adrenal insufficiency, and nerve damage. Despite these issues, patient-reported quality of life compared favorably with both cancer and general populations.²⁸

The persistent side effects that do stick around can meaningfully affect daily life. Patients with chronic immune-related side effects reported significantly lower quality-of-life scores compared to survivors without them.²⁹ This means that survivorship after immunotherapy is not simply about being alive; it involves managing a new baseline that may include lifelong hormone replacement, joint pain, or ongoing fatigue. These issues deserve the same attention as tumor outcomes in treatment planning.

The Cost of Staying on Treatment

Financial toxicity is an underappreciated factor in long-term immunotherapy outcomes. These drugs are expensive, and treatment courses often last one to two years. Cost-sharing policies have increased out-of-pocket expenses for patients, which in turn affects treatment adherence, quality of life, and even psychological health.³⁰ A patient who cannot afford to continue treatment is unlikely to achieve the durable responses that drive the long survival tails seen in clinical trials. Access to financial counseling and support programs is a practical issue that intersects directly with survival, and it deserves to be part of the conversation from the very start of treatment.